business

Novo Nordisk's Jamey Millar Discusses Wegovy's Impact on Medicare Access

24 Haziran 2026Bloomberg

Jamey Millar, Executive Vice President of US Operations at Novo Nordisk, addressed the company's strategies regarding the forthcoming CMS bridge program that will affect Medicare beneficiaries' access to obesity treatments. He expressed uncertainty about the pace of patient volume increase following the program's im…
Millar's insights were shared during an interview on 'The Close.'
The CMS bridge program is designed to enhance access to obesity treatments for Medicare beneficiaries, a demographic that has historically faced barriers in receiving such care. The successful rollout of this program could significantly alter the landscape of obesity treatment in the US, making it crucial for stakeh…
The anticipation surrounding the CMS bridge program reflects a critical juncture for obesity treatment accessibility in the US. Millar's acknowledgment of the uncertainty regarding patient volume highlights the complexities involved in healthcare policy implementation.

NewsAI özeti

This summary is based on information provided by Bloomberg and is intended for informational purposes only.

Tam teknik rapor ve canlı veriler için yayıncının web sitesini ziyaret edin.

Her yerde okuyun. iOS ve Android için ödüllü uygulamalarımızı indirin.